Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons

Journal of Lipid Research

Volumn 49, Issue 10, 2008, Pages 2250-2258

  Ryan, Scott D ^a,b   Harris, Cory S ^a,b   Carswell, Casey L ^b   Baenzinger, John E ^b   Bennett, Steffany A L ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Affinity; Analog; Antagonist; Central nervous system; Isoform inhibitor; Ligand; Neurodegeneration; Neurotoxicity; Receptor

Indexed keywords

2 ACETYL 1 O HEXADECYLGLYCEROPHOSPHORYLCHOLINE; 2 ACETYL 1 O OCTADECYLGLYCEROPHOSPHORYLCHOLINE; CASPASE 7; GLYCEROPHOSPHOLIPID; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; ENZYME ACTIVATION; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CARBON; CASPASES; CELL LINE; CEREBELLUM; GENE EXPRESSION REGULATION; MICE; MICELLES; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PHOSPHOLIPID ETHERS; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 58149393210     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800263-JLR200     Document Type: Article

References (60)

1. Prescott, S. M., G. A. Zimmerman, D. M. Stafforini, and T. M. McIntyre. 2000. Platelet activating factor and related lipid mediators. Annu. Rev. Biochem. 69: 419-445.
2. LipidMaps Consortium. 2007. Lipid metabolites and pathways strategy. Accessed June 11, 2008 at http://www.lipidmaps.org.
3. Tokumura, A., K. Takauchi, T. Asai, K. Kamiyasu, T. Ogawa, and H. Tsukatani. 1989. Novel molecular analogues of phosphatidylcholines in a lipid extract from bovine brain: 1-long-chain acyl-2-short-chain acyl-sn-glycero-3-phosphocholines. J. Lipid Res. 30: 219-224.
4. Mori, M., M. Aihara, K. Kume, M. Hamanoue, S. Kohsaka, and T. Shimizu. 1996. Predominant expression of platelet-activating factor receptor in rat brain microglia. J. Neurosci. 16: 3590-3600.
5. Bennett, S. A. L., J. Chen, B. A. Pappas, D. C. S. Roberts, and M. Tenniswood. 1998. Platelet activating factor receptor expression is associated with neuronal apoptosis in an in vivo model of excitotoxicity. Cell Death Differ. 5: 867-875.
6. Ishii, S., and T. Shimizu. 2000. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog. Lipid Res. 39: 41-82.
7. Ryan, S. D., C. S. Harris, F. Mo, H. Lee, S. T. Hou, N. G. Bazan, P. S. Haddad, J. T. Arnason, and S. A. L. Bennett. 2007. Platelet activating factor-induced neuronal apoptosis is initiated independently of its G-protein coupled PAF receptor and is inhibited by the benzoate orsellinic acid. J. Neurochem. 103: 88-97.
8. Perry, S. W., J. A. Hamilton, L. W. Tjoelker, G. Dbaibo, K. A. Dzenko, L. G. Epstein, Y. Hannun, J. S. Whittaker, S. Dewhurst, and H. A. Gelbard. 1998. Platelet activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J. Biol. Chem. 273: 17660-17664.
9. O'Flaherty, J. T., T. Tessner, D. Greene, J. R. Redman, and R. L. Wykle. 1994. Comparison of 1-O-alkyl-, 1-O-alk-1'-enyl-, and 1-Oacyl-2-acetyl-sn- glycero-3-phosphoethanolamines and -3-phosphocholines as agonists of the platelet-activating factor family. Biochim. Biophys. Acta. 1210: 209-216.
10. Carolan, E. J., and T. B. Casale. 1990. Degree of platelet activating factor-induced neutrophil migration is dependent upon the molecular species. J. Immunol. 145: 2561-2565.
11. Hwang, S. B., M. H. Lam, and A. H. Hsu. 1989. Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H] L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors. Mol. Pharmacol. 35: 48-58.
12. Ishii, I., T. Izumi, H. Tsukamoto, H. Umeyama, M. Ui, and T. Shimizu. 1997. Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. J. Biol. Chem. 272: 7846-7854.
13. Stoddart, N. R., W. E. Roudebush, and S. D. Fleming. 2001. Exogenous platelet-activating factor stimulates cell proliferation in mouse pre-implantation embryos prior to the fourth cell cycle and shows isoform-specific stimulatory effects. Zygote. 9: 261-268.
14. Handa, R. K., J. W. Strandhoy, and V. M. Buckalew, Jr. 1991. Vaso-relaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat. Life Sci. 49: 747-752.
15. Erger, R. A., and T. B. Casale. 1996. Eosinophil migration in response to three molecular species of platelet activating factor. Inflamm. Res. 45: 265-267.
16. Li, T., M. D. Southall, Q. Yi, Y. Pei, D. Lewis, M. Al-Hassani, D. Spandau, and J. B. Travers. 2003. The epidermal platelet-activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines. J. Biol. Chem. 278: 16614-16621.
17. Southall, M. D., J. S. Isenberg, H. Nakshatri, Q. Yi, Y. Pei, D. F. Spandau, and J. B. Travers. 2001. The platelet-activating factor receptor protects epidermal cells from tumor necrosis factor (TNF) alpha and TNF-related apoptosis-inducing ligand-induced apoptosis through an NF-kappa B-dependent process. J. Biol. Chem. 276: 45548-45554.
18. Brewer, C., F. Bonin, B. Bullock, M-C. Nault, J. Morin, S. Imbeault, T. Y. Shen, D. J. Franks, and S. A. L. Bennett. 2002. Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor. J. Neurochem. 82: 1502-1511.
19. Bonin, F., S. D. Ryan, L. Migahed, F. Mo, J. Lallier, D. J. Franks, H. Arai, and S. A. L. Bennett. 2004. Anti-apoptotic actions of the platelet activating factor acetylhydrolase I alpha 2 catalytic subunit. J. Biol. Chem. 279: 52425-52436.
20. Heusler, P., and G. Boehmer. 2007. Platelet-activating factor contributes to the induction of long-term potentiation in the rat somatosensory cortex in vitro. Brain Res. 1135: 85-91.
21. Chen, C., J. C. Magee, V. Marcheselli, M. Hardy, and N. G. Bazan. 2001. Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor. J. Neurophysiol. 85: 384-390.
22. Bazan, N. G., B. Tu, and E. B. Rodriguez de Turco. 2002. What synaptic lipid signaling tells us about seizure-induced damage and epileptogenesis. Prog. Brain Res. 135: 175-185.
23. Birkle, D. L., P. Kurian, P. Braquet, and N. G. Bazan. 1998. Platelet activating factor antagonist BN52021 decreases accumulation of free polyunsaturated fatty acid in mouse brain during ischemia and electroconvulsive shock. J. Neurochem. 51: 1900-1905.
24. Klein, J. 2000. Membrane breakdown in acute and chronic neuro-degeneration: focus on choline-containing phospholipids. J. Neural Transm. 107: 1027-1063.
25. Kanfer, J. N., G. Sorrentino, and D. S. Sitar. 1998. Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease. Neurosci. Lett. 257: 93-96.
26. Sweet, R. A., K. Panchalingam, J. W. Pettegrew, R. J. McClure, R. L. Hamilton, O. L. Lopez, D. I. Kaufer, S. T. DeKosky, and W. E. Klunk. 2002. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol. Aging. 23: 547-553.
27. Farooqui, A. A., and L. A. Horrocks. 2006. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist. 12: 245-260.
28. Watanabe, S., M. Doshi, K. Akimoto, Y. Kiso, and T. Hamazaki. 2001. Suppression of platelet-activating factor generation and modulation of arachidonate metabolism by dietary enrichment with (n-9) eicosatrienoic acid or docosahexaenoic acid in mouse peritoneal cells. Prostaglandins Other Lipid Mediat. 66: 109-120.
29. Lu, J., M. S. Caplan, D. Li, and T. Jilling. 2008. Polyunsaturated fatty acids block platelet-activating factor-induced phosphatidylinositol 3 kinase/Akt-mediated apoptosis in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294: 1181-1190.
30. Calon, F., G. P. Lim, F. Yang, T. Morhara, B. Teter, O. Ubeda, P. Rostaing, A. Triller, N. Salem, Jr., K. H. Ashe, et al. 2004. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 43: 633-645.
31. Igbavboa, U., J. Hamilton, H. Y. Kim, G. Y. Sun, and W. G. Wood. 2002. A new role for apolipoprotein E: modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J. Neurochem. 80: 255-261.
32. Callea, L., M. Arese, A. Orlandini, C. Bargnani, A. Priori, and F. Bussolino. 1999. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 94: 212-221.
33. Rouser, G., A. N. Siakotos, and S. Fleischer. 1966. Quantitative analysis of phospholipids by thin-layer chromatography and phosphorus analysis of spots. Lipids. 1: 85-86.
34. Ishii, S., T. Kuwaki, T. Nagase, K. Maki, F. Tashiro, S. Sunaga, W-H. Cao, K. Kume, Y. Fukuchi, K. Ikuta, et al. 1998. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet activating factor receptor. J. Exp. Med. 187: 1779-1788.
35. Ammitt, A. J., and C. O'Neill. 1997. Studies of the nature of the binding by albumin of platelet-activating factor released from cells. J. Biol. Chem. 272: 18772-18778.
36. Thornberry, N. A., T. A. Rano, E. P. Peterson, D. M. Rasper, T. Timkey, M. Garcia-Calvo, V. M. Houtzager, P. A. Nordstrom, S. Roy, J. P. Vaillancourt, et al. 1997. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272: 17907-17911.
37. Bellizzi, M. J., S. M. Lu, E. Masliah, and H. A. Gelbard. 2005. Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J. Clin. Invest. 115: 3185-3192.
38. Zhu, P., M. A. DeCoster, and N. G. Bazan. 2004. Interplay among platelet-activating factor, oxidative stress, and group I metabotropic glutamate receptors modulates neuronal survival. J. Neurosci. Res. 77: 525-531.
39. Okumura, N., A. Fukushima, A. Igarashi, T. Sumi, T. Yamagishi, and H. Ueno. 2006. Pharmacokinetic analysis of platelet-activating factor in the tears of guinea pigs with allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 22: 347-352.
40. Travers, J. B., C. Johnson, K. L. Clay, K. Harrison, T. Zekman, J. G. Morelli, and R. C. Murphy. 1997. Identification of sn-2 acetyl glycerophosphocholines in human keratinocytes. J. Lipid Mediat. Cell Signal. 16: 139-145.
41. Whitehead, S. N., W. Hou, M. Ethier, J. C. Smith, A. Bourgeois, R. Denis, S. A. L. Bennett, and D. Figeys. 2007. Rapid identification and quantitation of changes in the platelet activating factor family of glycerophospholipids over the course of neuronal differentiation by high performance liquid chromatography electrospray ionization tandem mass spectrometry. Anal. Chem. 79: 8539-8548.
42. Marcheselli, V. L., M. Rossowska, M. T. Domingo, P. Braquet, and N. G. Bazan. 1990. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J. Biol. Chem. 265: 9140-9145.
43. Hirashima, Y., N. Kuwayama, H. Hamada, N. Hayashi, and S. Endo. 2002. Etizolam, an anti-anxiety agent, attenuates recurrence of chronic subdural hematoma-evaluation by computed tomography. Neurol. Med. Chir. (Tokyo). 42: 53-55.
44. Brochet, B., P. Guinot, J. M. Orgogozo, C. Confavreux, L. Rumbach, and V. Lavergne. 1995. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 58: 360-362.
45. Akisu, M., A. Huseyinov, M. Yalaz, H. Cetin, and N. Kultursay. 2003. Selective head cooling with hypothermia suppresses the generation of platelet-activating factor in cerebrospinal fluid of newborn infants with perinatal asphyxia. Prostaglandins Leukot. Essent. Fatty Acids. 69: 45-50.
46. Hirashima, Y., S. Endo, H. Nukui, N. Kobayashi, and A. Takaku. 2001. Effect of a platelet-activating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage-open clinical trial to investigate efficacy and safety. Neurol. Med. Chir. (Tokyo). 41: 165-175.
47. DeKosky, S. T., A. Fitzpatrick, D. G. Ives, J. Saxton, J. Williamson, O. L. Lopez, G. Burke, L. Fried, L. H. Kuller, J. Robbins, et al. 2006. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp. Clin. Trials. 27: 238-253.
48. Ponto, L. L., and S. K. Schultz. 2003. Ginkgo biloba extract: review of CNS effects. Ann. Clin. Psychiatry. 15: 109-119.
49. Dupré, D. J., C. Le Gouill, M. Rola-Pleszczynski, and J. Stanková. 2001. Inverse agonist activity of selected ligands of platelet activating factor receptor. J. Pharmacol. Exp. Ther. 2999: 358-365.
50. Pinckard, R. N., H. J. Showell, R. Castillo, C. Lear, R. Breslow, L. M. McManus, D. S. Woodard, and J. C. Ludwig. 1992. Differential responsiveness of human neutrophils to the autocrine actions of 1-O-alkyl-homologs and 1-acyl analogs of platelet-activating factor. J. Immunol. 148: 3528-3535.
51. Satouchi, K., R. N. Pinckard, and D. J. Hanahan. 1981. Influence of alkyl ether chain length of acetyl glyceryl ether phosphorylcholine and its ethanolamine analog on biological activity toward rabbit platelets. Arch. Biochem. Biophys. 211: 683-688.
52. Ishii, S., T. Nagase, F. Tashiro, K. Ikuta, S. Sato, I. Waga, K. Kume, J. Miyazaki, and T. Shimizu. 1997. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgeneic mice overexpressing platelet-activating factor receptor. EMBO J. 16: 133-142.
53. Shen, T. Y., S-B. Hwang, T. W. Doebber, and J. C. Robbins. 1987. The chemical and biological properties of PAF agonists, antagonists, and biosynthetic inhibitors. In Platelet Activating Factor and Related Lipid Mediators. F. Snyder, editor. Plenum Press, New York. 153-190.
54. Braquet, P., and J. J. Godfroid. 1987. Conformation properties of the PAF-acether receptor based on structure-activity studies. In Platelet Activating Factor and Related Lipid Mediators. F. Snyder, editor. Plenum Press, New York. 191-235.
55. Svetlov, S. I., K. M. Howard, M. Miwa, B. D. Flickinger, and M. S. Olson. 1996. Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation. Arch. Biochem. Biophys. 327: 113-122.
56. Chen, J., L. Yang, J. M. Foulks, A. S.Weyrich, G. K. Marathe, and T. M. McIntyre. 2007. Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis. J. Lipid Res. 48: 2365-2376.
57. Ohshima, N., S. Ishii, T. Izumi, and T. Shimizu. 2002. Receptor-dependent metabolism of platelet-activating factor in murine macrophages. J. Biol. Chem. 277: 9722-9727.
58. Kravchenko, V. V., Z. Pan, J. Han, J. M. Herbert, R. J. Ulevitch, and R. D. Ye. 1995. Platelet-activating factor induces NF-kappaB activation through a G protein-coupled pathway. J. Biol. Chem. 270: 14928-14934.
59. Okano, H., K. Shiraki, H. Inoue, Y. Yamanaka, T. Kawakita, Y. Saitou, Y. Yamaguchi, N. Enokimura, N. Yamamoto, K. Sugimoto, et al. 2003. 15-Deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab. Invest. 83: 1529-1539.
60. Hughes, A. L., D. Messineo-Jones, S. P. Lad, and K. E. Neet. 2001. Distinction between differentiation, cell cycle, and apoptosis signals in PC12 cells by the nerve growth factor mutant delta9/13, which is selective for the p75 neurotrophin receptor. J. Neurosci. Res. 63: 10-19.